Accelerating Precision Medicine™

POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer

What is Nuclear Medicine?

Improving cancer outcomes with Radioligand Therapies

POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Radioligands offer improved efficacy and superior safety profiles versus platform chemotherapy agents and can provide patients and their families the very best possible outcomes.

Learn about POINT Biopharma

The Science of Radioligand Therapy

Although it may seem futuristic, radioligand therapy is a safe and proven treatment method for a variety of cancers.

First a scan is performed

Next the drug is administered

The drug then seeks out cancer

Learn about Radioligand Therapies

Our Treatment Pipeline

We are dedicated to expanding access to radiology therapies, making them applicable to more cancers, accessible to more people, and improving the lives of patients and their families. Here are the compounds we are currently developing:
Two people hugging

Help improve the lives of patients and their families

We are hiring for clinical, manufacturing and business roles:
Careers at POINT Biopharma

News

POINT Biopharma and TerraPower Sign Supply Agreement for Actinium-225

POINT announced today they signed a research and clinical supply agreement with TerraPower for the medical radioisotope actinium-225 (Ac-225)

Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I

POINT Biopharma has entered into a definitive merger agreement with Research Alliance Corp. I (Nasdaq: RACA). Upon closing, the combined company is expected to be listed on Nasdaq under the ticker symbol “PNT”.

POINT Biopharma signs exclusive license agreement with CanProbe for the commercialization of a neuroendocrine tumor treatment

Today it was announced that POINT has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium – 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer.